S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.14%) $0.928
USD/NOK
(0.32%) $10.88
USD/GBP
(0.01%) $0.792
USD/RUB
(0.02%) $92.59

Realtime updates for Amphastar Pharmaceuticals [AMPH]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
BUY
100.00%
return 4.23%
SELL
50.00%
return -2.48%
Last Updated28 Mar 2024 @ 16:00

0.90% $ 43.91

SELL 64163 min ago

@ $55.32

Issued: 13 Feb 2024 @ 11:06


Return: -20.62%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 0.69 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France...

Stats
Today's Volume 453 248
Average Volume 490 447
Market Cap 2.11B
EPS $0 ( 2024-02-27 )
Next earnings date ( $0 ) 2024-05-07
Last Dividend $0.300 ( 2010-06-11 )
Next Dividend $0 ( N/A )
P/E 16.89
ATR14 $0.0340 (0.08%)
Insider Trading
Date Person Action Amount type
2024-03-15 Zhang Jack Y. Buy 722 046 Common Stock
2024-03-15 Zhang Jack Y. Sell 408 721 Common Stock
2024-03-17 Zhang Jack Y. Sell 15 768 Common Stock
2024-03-15 Zhang Jack Y. Buy 310 930 Common Stock
2024-03-15 Zhang Jack Y. Sell 202 658 Common Stock
INSIDER POWER
-2.71
Last 100 transactions
Buy: 1 579 536 | Sell: 1 726 974

Volume Correlation

Long: -0.42 (neutral)
Short: -0.66 (moderate negative)
Signal:(24.359) Neutral

Amphastar Pharmaceuticals Correlation

10 Most Positive Correlations
LMNR0.96
PDFS0.955
RCEL0.953
GEOS0.953
ALTR0.951
VTYX0.951
ERII0.95
SLMBP0.95
PANL0.946
ANSS0.945
10 Most Negative Correlations
CSSEP-0.95
NAKD-0.95
ALXO-0.95
MICS-0.95
BLUE-0.946
CBNK-0.944
PMVP-0.943
CMLS-0.94
BWB-0.94
FGBI-0.939

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amphastar Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.45
( neutral )
The country flag 0.23
( neutral )
The country flag 0.00
( neutral )
The country flag 0.71
( moderate )
The country flag -0.37
( neutral )
The country flag 0.28
( neutral )

Amphastar Pharmaceuticals Financials

Annual 2023
Revenue: $644.40M
Gross Profit: $343.97M (53.38 %)
EPS: $2.85
Q4 2023
Revenue: $178.11M
Gross Profit: $93.57M (52.53 %)
EPS: $0.750
Q3 2023
Revenue: $180.56M
Gross Profit: $108.40M (60.04 %)
EPS: $1.010
Q2 2023
Revenue: $145.71M
Gross Profit: $72.74M (49.92 %)
EPS: $0.540

Financial Reports:

No articles found.

Amphastar Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Amphastar Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.10 - Potential for dividend initiation, but uncertain (2.04%)
Information
First Dividend $0.300 2009-06-11
Last Dividend $0.300 2010-06-11
Next Dividend $0 N/A
Payout Date 2010-06-30
Next Payout Date N/A
# dividends 2 --
Total Paid Out $0.600 --
Avg. Dividend % Per Year 0.00% --
Score 2.95 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.10
Div. Directional Score 8.08 --
Next Divdend (Est)
(2025-03-28)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
2.95
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2131.5005.738.60[0 - 0.5]
returnOnAssetsTTM0.09091.2006.978.36[0 - 0.3]
returnOnEquityTTM0.2321.5008.5310.00[0.1 - 1]
payoutRatioTTM0.120-1.0008.80-8.80[0 - 1]
currentRatioTTM2.170.8004.143.31[1 - 3]
quickRatioTTM1.6600.8004.943.95[0.8 - 2.5]
cashRatioTTM0.6411.5007.5510.00[0.2 - 2]
debtRatioTTM0.392-1.5003.46-5.19[0 - 0.6]
interestCoverageTTM9.501.0007.597.59[3 - 30]
operatingCashFlowPerShareTTM3.462.008.8510.00[0 - 30]
freeCashFlowPerShareTTM2.742.008.6310.00[0 - 20]
debtEquityRatioTTM0.928-1.5006.29-9.43[0 - 2.5]
grossProfitMarginTTM0.5411.0004.324.32[0.2 - 0.8]
operatingProfitMarginTTM0.2941.0006.126.12[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3091.0009.399.39[0.2 - 2]
assetTurnoverTTM0.4260.800-0.494-0.395[0.5 - 2]
Total Score11.07

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM16.771.0008.410[1 - 100]
returnOnEquityTTM0.2322.509.0610.00[0.1 - 1.5]
freeCashFlowPerShareTTM2.742.009.0910.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM3.462.008.8510.00[0 - 30]
payoutRatioTTM0.1201.5008.80-8.80[0 - 1]
pegRatioTTM0.2231.500-1.8460[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2851.0005.380[0.1 - 0.5]
Total Score5.10

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators